The United States Food and Drug Administration (FDA) has approved Novartis Pharmaceuticals Corporation’s Pluvicto in combination with androgen receptor pathway inhibitor therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer, moving targeted radioligand therapy into an earlier stage of the disease.
The July 31 approval covers patients whose metastatic cancer remains responsive to androgen suppression or has not yet been exposed extensively to it. The FDA now describes this population as having metastatic androgen pathway modulation-naive or sensitive prostate cancer, although metastatic hormone-sensitive prostate cancer remains the more familiar clinical term.
Eligible patients must have PSMA-positive tumors identified with Locametz or another approved PSMA positron emission tomography product. Treatment consists of six intravenous Pluvicto doses administered six weeks apart alongside an androgen receptor pathway inhibitor, while medical or surgical suppression of testosterone continues.
The approval was supported by the randomized Phase 3 PSMAddition trial, in which the Pluvicto combination reduced the risk of radiographic progression or death by 28% at the primary analysis compared with an androgen receptor pathway inhibitor and androgen-deprivation therapy alone. An updated analysis reported by Novartis subsequently showed a 33% risk reduction, but overall-survival evidence remains immature and has not yet established a statistically conclusive survival advantage.
The decision transforms Pluvicto from a treatment principally associated with castration-resistant prostate cancer into an option spanning the metastatic disease continuum. It also creates a more difficult clinical question: which patients should receive six cycles of radioactive treatment immediately, and which can be managed with hormonal intensification or chemotherapy without taking on the additional burden?
What exactly has the FDA approved for earlier use of Novartis Pluvicto?
The expanded indication covers adults with PSMA-positive metastatic prostate cancer that is still sensitive to androgen pathway suppression or has not previously been treated substantially with such therapy.
Pluvicto must be combined with an androgen receptor pathway inhibitor. The PSMAddition study permitted investigators to select abiraterone, apalutamide, enzalutamide, darolutamide or another agent in the same class.
Patients must also maintain androgen deprivation. This can involve a gonadotropin-releasing hormone agonist or antagonist, or prior surgical removal of the testes. Pluvicto therefore adds a targeted radioactive component to the hormonal backbone rather than replacing testosterone suppression.
The recommended Pluvicto dose is 7.4 gigabecquerels, equivalent to 200 millicuries, every six weeks for six administrations. Treatment may end sooner if the cancer progresses or toxicity becomes unacceptable.
The FDA approved the application approximately one month before its target action date. The decision is a conventional approval based on a randomized Phase 3 study rather than an accelerated authorization dependent on an unverified surrogate from a single-arm trial.
Pluvicto was initially approved in 2022 for previously treated PSMA-positive metastatic castration-resistant prostate cancer. Its label was expanded in March 2025 to permit use after an androgen receptor pathway inhibitor and before taxane chemotherapy in patients considered appropriate to delay chemotherapy.
The latest decision moves treatment another step forward. Patients no longer need to demonstrate castration resistance before becoming eligible, provided their metastatic tumors meet the required PSMA imaging criteria.
How did the PSMAddition trial establish Pluvicto’s progression benefit?
PSMAddition enrolled 1,144 adults with PSMA-positive metastatic hormone-sensitive prostate cancer. Participants were randomly assigned in equal numbers to receive Pluvicto with an androgen receptor pathway inhibitor or the androgen receptor pathway inhibitor without Pluvicto.
Both groups continued androgen-deprivation therapy unless the patient had already undergone bilateral orchiectomy. This allowed the trial to test the contribution of radioligand therapy against an active hormonal treatment backbone rather than against undertreatment or androgen deprivation alone.
Patients could have received no more than 45 days of androgen deprivation, an androgen receptor pathway inhibitor or both in the metastatic setting before entering the study. This requirement positioned the trial close to the beginning of systemic treatment.
The primary endpoint was radiographic progression-free survival assessed by blinded independent central review. Progression could involve new or enlarging disease on imaging, while death was also counted as an event.
At the analysis supporting the FDA label, progression or death occurred in 139 of the 572 patients assigned to Pluvicto and in 172 of the 572 patients receiving the control regimen. The hazard ratio was 0.72, corresponding to a 28% reduction in the risk of radiographic progression or death.
The result was statistically significant, with a 95% confidence interval of 0.58 to 0.90 and a one-sided p-value of 0.002. Median radiographic progression-free survival had not yet been reached in either treatment group, indicating that insufficient patients had experienced an event to calculate a stable median duration.
A later analysis reported by Novartis produced a hazard ratio of 0.67, representing a 33% reduction in the risk of progression or death. That updated estimate strengthens confidence that the result did not disappear with further follow-up, although the FDA prescribing information is anchored to the prespecified analysis with the 0.72 hazard ratio.
Why does the immature overall-survival result remain an important limitation?
Radiographic progression-free survival measures how long patients remain alive without imaging showing disease progression. It can provide an earlier indication of treatment activity than overall survival, particularly in prostate cancer, where patients may receive several subsequent therapies.
Avoiding or delaying progression is clinically relevant. Progression can lead to bone pain, fractures, spinal-cord compression, urinary obstruction, additional treatment and declining physical function.
However, an improvement in imaging-based progression does not automatically mean patients live longer. A treatment can delay visible progression without producing a sufficiently large survival advantage, particularly if it adds toxicity or if patients in the control group later receive the same therapy.
At the FDA analysis, 291 patients across the study had died, representing approximately one-quarter of the randomized population. The overall-survival data were therefore considered immature.
Novartis reported an updated overall-survival hazard ratio of 0.80, with a 95% confidence interval from 0.63 to 1.01. The estimate numerically favors Pluvicto, but the confidence interval crosses 1.00, meaning a conclusive survival benefit has not yet been demonstrated.
Interpretation will also be affected by the trial’s crossover provision. Patients assigned to the control arm could receive Pluvicto after centrally confirmed radiographic progression. Crossover provides access to an active treatment but can narrow the observed survival difference between immediate and delayed Pluvicto use.
The final analysis must therefore answer a sequencing question rather than merely confirming that Pluvicto works. It must show whether delivering radioligand therapy during the hormone-sensitive stage produces a survival advantage over reserving it until progression.
How does Pluvicto deliver radioactive treatment to PSMA-positive cancer cells?
Pluvicto combines a targeting molecule with lutetium-177, a radioactive isotope that emits beta radiation. The targeting portion binds to prostate-specific membrane antigen, a protein expressed at high levels on many prostate cancer cells.
After intravenous administration, the compound circulates through the body and attaches to cells displaying PSMA. Lutetium-177 then releases radiation over a relatively short distance, damaging DNA in the targeted cell and nearby cancer cells.
This mechanism allows radiation to reach metastatic deposits in multiple locations through a systemic treatment. It differs from external-beam radiation, which directs energy toward anatomically defined areas from outside the body.
The approach is targeted but not perfectly tumor-specific. PSMA is also present in certain normal tissues, while the radioligand can pass through organs involved in distribution and elimination. The salivary glands, lacrimal glands, kidneys, urinary bladder and bone marrow can consequently receive radiation.
This helps explain characteristic adverse effects such as dry mouth, changes in blood counts and kidney-related concerns. The radiation range may limit exposure beyond the immediate area of uptake, but it does not eliminate damage to healthy tissue.
Pluvicto is primarily eliminated through the kidneys. Patients are advised to remain well hydrated and urinate frequently around treatment to reduce the time radioactive material remains in the urinary tract.
Why is PSMA PET imaging now a gateway to first-line Pluvicto treatment?
The FDA label requires selection with Locametz, whose active ingredient is gallium Ga 68 gozetotide, or another approved PSMA positron emission tomography product. A positive scan confirms that the patient’s tumors express enough of the intended target to make radioligand delivery biologically plausible.
PSMAddition required at least one metastatic lesion visible on conventional imaging and at least one tumor lesion with gallium Ga 68 gozetotide uptake greater than normal liver uptake. Patients were excluded when all identified liver metastases were PSMA-negative.
This matters because PSMA expression is not uniform. Different tumors in the same patient can display different levels of the target, and expression may change as disease evolves.
A patient with strongly PSMA-positive bone and lymph-node lesions may be a logical candidate. Someone with substantial PSMA-negative disease could receive inadequate radiation in important tumor deposits even if another lesion appears positive.
The imaging requirement turns the expanded approval into a diagnostic and therapeutic pathway. Urologists and medical oncologists must identify appropriate patients, arrange PSMA PET imaging and coordinate interpretation with nuclear-medicine specialists before treatment begins.
Access to scanning may become an early bottleneck. Communities without nearby PSMA PET capability or reliable radiotracer supply may struggle to identify eligible patients promptly, even if the treatment itself is technically available at a regional centre.
The scan also adds cost and scheduling complexity. Pluvicto’s clinical reach will depend not only on how many tumors express PSMA but also on whether the healthcare system can provide imaging, treatment capacity and insurance authorization at the beginning of metastatic care.
Could Pluvicto compete with chemotherapy-based treatment intensification?
Androgen-deprivation therapy remains the backbone of metastatic hormone-sensitive prostate cancer treatment, but androgen suppression alone is generally insufficient for patients fit enough to receive combination therapy.
Current treatment approaches frequently add an androgen receptor pathway inhibitor such as abiraterone, apalutamide, enzalutamide or darolutamide. Selected patients, particularly those with extensive or newly diagnosed metastatic disease, may receive docetaxel alongside androgen deprivation and an androgen receptor pathway inhibitor.
Pluvicto introduces another intensification option. It may appeal to patients for whom chemotherapy is undesirable, although PSMAddition was not designed as a direct comparison between Pluvicto and docetaxel.
The study compared Pluvicto plus hormonal treatment with hormonal treatment alone. It cannot establish that the radioligand combination produces better survival, quality of life or safety than a docetaxel-containing triplet.
Treatment selection will therefore remain individualized. Disease volume, symptoms, age, performance status, kidney function, bone-marrow reserve, previous local treatment, genomic findings and patient preference may all affect the decision.
Radioligand therapy is not automatically the gentler option. Pluvicto avoids several familiar chemotherapy toxicities, but it exposes patients to radiation, repeated nuclear-medicine visits, dry mouth, nausea and potentially clinically important blood-count suppression.
It also occupies a treatment mechanism that might otherwise remain available after the cancer becomes resistant to androgen suppression. Clinicians must weigh whether using Pluvicto early delivers enough additional benefit to justify reducing uncertainty about later retreatment or sequencing.
Did patients with both high-volume and low-volume disease appear to benefit?
Approximately 70% of patients in the FDA population had high-volume metastatic disease, while 30% had low-volume disease. More than half presented with metastatic cancer at their initial diagnosis, while the remainder had recurrence after earlier localized disease.
Subgroup analyses reported during the 2026 American Society of Clinical Oncology meeting found hazard ratios of 0.72 in high-volume disease and 0.73 in low-volume disease. The point estimates were nearly identical, suggesting that the relative effect was not restricted to patients with extensive metastases.
The confidence interval for low-volume disease was wider and crossed 1.00, reflecting fewer patients and fewer progression events. This does not prove that Pluvicto lacks benefit in low-volume disease, but it limits the precision of the estimate.
Results also appeared directionally consistent between newly diagnosed metastatic cancer and recurrent metastatic disease. Neither subgroup analysis was independently powered to provide the same certainty as the overall randomized result.
The distinction matters because absolute benefit can vary even when relative hazard ratios look similar. A patient with aggressive high-volume disease may face earlier progression and therefore gain more months without progression from the same proportional reduction in risk.
Patients with lower-volume disease may remain controlled for longer with hormonal therapy alone. For them, immediate radioligand treatment must be weighed against the possibility of preserving Pluvicto for a later disease stage.
Longer follow-up should help identify whether early use benefits broad PSMA-positive populations or produces its most meaningful clinical value in patients with a particular disease burden, metastatic pattern or response to initial androgen suppression.
What safety risks accompany six early cycles of Pluvicto treatment?
The expanded label contains warnings covering radiation exposure, bone-marrow suppression, kidney toxicity, embryo-fetal harm and infertility.
In PSMAddition, serious adverse reactions occurred in 32% of patients receiving Pluvicto with an androgen receptor pathway inhibitor. Eight percent permanently discontinued Pluvicto because of adverse reactions, with anemia the most frequent individual reason.
Fatigue occurred in 51% of patients receiving the Pluvicto combination compared with 41% in the control group. Dry mouth occurred in 46% compared with 3.7%, while nausea affected 34% compared with 9%.
Laboratory abnormalities illustrate the treatment’s effect on bone marrow. Decreased lymphocyte counts occurred in 91% of patients in the Pluvicto group and reached grade 3 or 4 severity in 24%. Decreased hemoglobin occurred in 72%, decreased neutrophils in 41% and decreased platelets in 23%.
Severe reductions were less frequent but remain clinically relevant. Grade 3 or 4 decreases occurred in 7% for leukocytes, 4.4% for neutrophils, 4.3% for hemoglobin and 1.1% for platelets.
Kidney function must be checked before and during treatment. Grade 3 or 4 acute kidney injury occurred in 1.6% of Pluvicto-treated patients in PSMAddition.
Radiation precautions extend beyond the infusion centre. After each administration, patients must temporarily limit close contact with other people, particularly children and pregnant women, and follow instructions concerning sleeping arrangements and sexual activity.
These requirements may be manageable for many patients, but they are not trivial. Household composition, caregiving duties, living space and the ability to understand radiation-safety instructions can influence whether treatment is practical.
Can radiopharmaceutical manufacturing and hospital capacity support wider demand?
Pluvicto is not an ordinary medicine that can sit on a pharmacy shelf for an extended period. Lutetium-177 decays continuously, meaning each dose must be produced, transported and administered within a controlled time window.
Treatment sites need appropriately licensed personnel, radiation-protected facilities, contamination procedures and systems for handling radioactive waste. Medical oncologists must coordinate with nuclear medicine, radiology, pharmacy and radiation-safety teams.
Earlier eligibility could substantially increase demand because patients may now receive Pluvicto soon after metastatic diagnosis rather than waiting for castration-resistant disease. Novartis estimates that the expanded label nearly doubles the eligible population.
The company has disclosed five United States radioligand manufacturing sites that are operational or under construction. It has also said that its distribution network can deliver Pluvicto to United States treatment centres within five days.
Manufacturing expansion is important because radioligand therapy has previously faced supply constraints. Additional capacity must translate into dependable doses arriving on the correct day, since cancellations can disrupt a six-cycle schedule and burden patients travelling considerable distances.
The larger access challenge may shift from production to treatment-site capacity. A hospital can receive more doses without necessarily having enough infusion appointments, nuclear-medicine specialists or radiation-isolation space to administer them.
Community access will determine whether the approval changes routine care or remains concentrated in academic centres. Referral systems must allow patients diagnosed by urologists or community oncologists to reach qualified radioligand facilities before their disease progresses.
What must mature PSMAddition data prove after this FDA approval?
The final overall-survival analysis is the most consequential remaining result. A statistically convincing survival advantage would support immediate treatment intensification and make the case for using Pluvicto before castration resistance considerably stronger.
Investigators must also clarify sequencing. It remains uncertain how effectively patients can receive Pluvicto again after earlier six-cycle exposure, whether another PSMA-targeted radioligand remains useful and how early treatment affects later responses to chemotherapy, targeted medicines or other radioactive agents.
Long-term bone-marrow safety deserves particular attention. Patients treated during the hormone-sensitive stage may live for years and receive several additional systemic therapies. Even moderate early marrow damage could influence their ability to tolerate later chemotherapy or other radiopharmaceuticals.
Secondary cancers are another long-term concern because ionizing radiation is carcinogenic and mutagenic. Their frequency cannot be characterized adequately through relatively short follow-up in a population with advanced cancer.
The trial must also show whether delaying radiographic progression translates into delayed pain, skeletal complications, treatment escalation and functional decline. Available patient-reported analyses suggest broadly similar quality-of-life trajectories between the treatment groups, despite a temporary treatment burden during the six-cycle course.
The FDA approval establishes Pluvicto as an earlier precision-treatment option, but it does not dictate that every eligible patient should receive it immediately. The strongest candidates may be patients with clearly PSMA-avid disease, substantial progression risk, adequate kidney and marrow function and a preference for targeted radioligand therapy over chemotherapy.
For prostate cancer care, the decision confirms that radioligand therapy is moving from salvage treatment toward the front of the therapeutic sequence. The remaining question is whether earlier radioactive targeting merely postpones progression or changes the course of metastatic disease enough to help patients live longer.
That answer will come from mature survival evidence, longer safety follow-up and real-world access. The approval opens the door. PSMAddition must still show how far walking through it takes patients.
